Regeneron Pharmaceuticals has delivered a 28.2% return over the past year, yet its valuation checks still lean toward the stock looking inexpensive rather than stretched. That sits against a backdrop of mixed sentiment, with recent legal action around a failed melanoma trial raising questions about how much risk is already reflected in the current share price.

• Regeneron Pharmaceuticals is up 28.2% over the past year, which puts recent shareholders in profit and is prompting closer scrutiny of whether the current price still offers value.
• On the one hand, progress in areas such as food allergy treatments can support long term earnings power. On the other hand, the securities class action linked to the Phase III melanoma trial and the related loss of around US$11b in market value highlight ongoing legal and pipeline risks that may weigh on what investors are willing to pay.
• Regeneron Pharmaceuticals scores highly on the broader valuation checks, with 5 out of 6 tests pointing to the stock trading on the cheap side rather than at a clear premium.

The issue now is whether Regeneron Pharmaceuticals' current valuation still leaves enough room for setbacks in its pipeline and legal outcomes, or whether the recent share price strength has already used up most of that cushion.

Does Regeneron Pharmaceuticals Look Undervalued on Earnings?

The P/E ratio suits Regeneron Pharmaceuticals because earnings are a key driver of how investors judge large, established biopharma stocks. Regeneron currently trades on a P/E of 16.0x, which sits slightly below the Biotechs industry average of about 16.5x and well below the peer group average of 21.2x. That alone suggests the market is not paying a clear premium for the company relative to similar stocks.

The fair P/E ratio implied by the broader checks is 25.1x, which is well ahead of where Regeneron trades today. This indicates a sizeable gap between the multiple suggested by its characteristics and the price investors are actually paying. Despite the overhang from the ongoing securities class action around the melanoma trial, the shares still change hands at a discount to this tailored fair value marker.

On this P/E yardstick, Regeneron Pharmaceuticals stock appears undervalued compared with both peers and the fair multiple implied by its profile.

The Regeneron Pharmaceuticals Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where this Regeneron Pharmaceuticals valuation puzzle leaves off. They spell out which future assumptions on growth, margins and earnings would need to hold for the stock to be worth materially more or less than today’s price on the Community page. Each one sets out a fair value as a thesis about Regeneron Pharmaceuticals' business that you can track over time and see how well it holds up against events.

Community views on Regeneron Pharmaceuticals sit far apart, with one side focused on pipeline strength and the other on product concentration and pricing pressure.

Bull case: 17% undervalued

"Regeneron's broad and advancing pipeline including recent or upcoming pivotal data in immunology, oncology, genetic medicines, and obesity positions the company to benefit from demographic-driven increases in demand for advanced therapies..."

Bear case: 8% overvalued

"Regeneron's heavy reliance on EYLEA and now EYLEA HD for a substantial portion of overall revenues leaves it acutely vulnerable to mounting biosimilar competition and alternative therapies following patent expirations..."

Do you think there's more to the story for Regeneron Pharmaceuticals? Head over to our Community to see what others are saying!

The Bottom Line

Regeneron Pharmaceuticals screens as undervalued on market multiples, with the current P/E sitting below both peers and the fair ratio suggested by broader checks. That gap reflects how legal and pipeline risks are still influencing what investors are willing to pay. For you, the key question is whether those risks prove contained enough for the valuation discount to narrow over time, or whether product concentration and litigation concerns keep a lid on the multiple. The crux of the bull versus bear debate is whether Regeneron Pharmaceuticals can sustain and diversify its earnings base enough to justify investors paying closer to that implied fair P/E.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.